文献速递淋巴瘤

基于18F-FDG PET影像组学的预后模型预测复发/难治性霍奇金淋巴瘤无进展生存期

Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

研究利用基线18F-FDG PET影像组学特征与临床特征构建预后模型,在2项临床试验共113例复发/难治性经典型霍奇金淋巴瘤患者中训练,并在69例外部队列中验证。模型可识别高风险进展患者,训练队列3年PFS高风险组38.1% vs 低风险组88.4%(P < .001),验证队列38.5% vs 75.0%(P = .015),低风险组总生存也显著更优。

要点

  • 模型基于基线PET影像组学与临床特征,训练集113例,外部验证集69例。
  • 训练队列3年PFS高风险组38.1% vs 低风险组88.4%(P < .001)。
  • 验证队列3年PFS高风险组38.5% vs 低风险组75.0%(P = .015)。

核心结论

  • 研究在较大复发/难治性经典型霍奇金淋巴瘤队列中构建了结合影像组学与临床特征的PFS预后模型,可计算基于PET的风险评分,并可用于制定风险分层治疗策略。

研究设计与样本

  • 利用基线定量18F-FDG PET影像组学特征与临床特征构建预后模型,训练集为2项临床试验共113例接受挽救化疗后自体干细胞移植的复发/难治性经典型霍奇金淋巴瘤患者。
  • 模型在69例独立外部队列中验证,并验证了4种不同的PET分割方法计算影像组学特征。

主要发现

  • 训练队列中高风险组3年PFS为38.1%,低风险组为88.4%(P < .001)。
  • 验证队列中高风险组3年PFS为38.5%,低风险组为75.0%(P = .015)。
  • 低风险组总生存也显著更优(训练队列P = .022,验证队列P < .001)。
  • 研究提供了基于模型计算个体患者风险评分的公式。

关键数值与推荐

  • 模型使用代谢肿瘤体积及多个新影像组学播散特征(反映病灶间距离、体积和标准摄取值差异)。
  • 采用后向选择与逻辑回归的机器学习方法开发并训练模型。

临床怎么用

  • 原文结论指出该模型可计算基于PET的风险特征,并可用于为复发/难治性经典型霍奇金淋巴瘤患者制定风险分层治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Investigating prognostic factors in patients with relapsed or primary refractory classical Hodgkin lymphoma (R/R cHL) is essential to optimize risk-adapted treatment strategies. We built a prognostic model using baseline quantitative 18F-fluorodeoxyglucose positron emission tomography (PET) radiomics features and clinical characteristics to predict the progression-free survival (PFS) among patients with R/R cHL treated with salvage chemotherapy followed by autologous stem cell transplantation. Metabolic tumor volume and several novel radiomics dissemination features, representing interlesional differences in distance, volume, and standard uptake value, were extracted from the baseline PET. Machine learning using backward selection and logistic regression were applied to develop and train the model on a total of 113 patients from 2 clinical trials. The model was validated on an independent external cohort of 69 patients. In addition, we validated 4 different PET segmentation methods to calculate radiomics features. We identified a subset of patients at high risk for progression with significant inferior 3-year PFS outcomes of 38.1% vs 88.4% for patients in the low-risk group in the training cohort (P < .001) and 38.5% vs 75.0% in the validation cohort (P = .015), respectively. The overall survival was also significantly better in the low-risk group (P = .022 and P < .001). We provide a formula to calculate a risk score for individual patients based on the model. In conclusion, we developed a prognostic model for PFS combining radiomics and clinical features in a large cohort of patients with R/R cHL. This model calculates a PET-based risk profile and can be applied to develop risk-stratified treatment strategies for patients with R/R cHL. These trials were registered at www.clinicaltrials.gov as #NCT02280993, #NCT00255723, and #NCT01508312.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Driessen J, Zwezerijnen GJC, Schöder H, et al. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2023. PMID: 37722357. doi:10.1182/bloodadvances.2023010404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。